SBIJI Innovation - Under the terms of the research collaboration and exclusive option agreement, the companies will initiate a gene editing research program dedicated to the treatment of two early onset indications with high unmet need, leveraging the GeneRide™ platform -
ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase 1b Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002 NEW YORK, Friday August 27, 2021 Read More
MONMOUTH JUNCTION, N.J. and AIRPORT CITY, Israel, July 06, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (“Advaxis”) (NASDAQ: ADXS) and Biosight Ltd. (“Biosight”), a privately held pharmaceutical development
LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia June 2, 2021 at 7:0